Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Total Liabilities
Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has total liabilities worth CN¥4.55 Billion CNY (≈ $666.04 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Shenzhen Hepalink Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Shenzhen Hepalink Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Shenzhen Hepalink Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ourpalm
SHE:300315
|
China | CN¥410.75 Million |
|
ACME Solar Holdings Limited
NSE:ACMESOLAR
|
India | Rs156.42 Billion |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
China | CN¥3.42 Billion |
|
Austevoll Seafood ASA
OL:AUSS
|
Norway | Nkr37.08 Billion |
|
Xinhuanet Co Ltd
SHG:603888
|
China | CN¥1.25 Billion |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
India | Rs52.36 Billion |
|
East Group Co Ltd
SHE:300376
|
China | CN¥6.43 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002399 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Hepalink Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.55 Billion ≈ $666.04 Million |
-11.47% |
| 2024-12-31 | CN¥5.14 Billion ≈ $752.35 Million |
-28.74% |
| 2023-12-31 | CN¥7.22 Billion ≈ $1.06 Billion |
-14.17% |
| 2022-12-31 | CN¥8.41 Billion ≈ $1.23 Billion |
+10.83% |
| 2021-12-31 | CN¥7.58 Billion ≈ $1.11 Billion |
+3.38% |
| 2020-12-31 | CN¥7.34 Billion ≈ $1.07 Billion |
-5.59% |
| 2019-12-31 | CN¥7.77 Billion ≈ $1.14 Billion |
+4.87% |
| 2018-12-31 | CN¥7.41 Billion ≈ $1.08 Billion |
+34.66% |
| 2017-12-31 | CN¥5.50 Billion ≈ $805.23 Million |
+14.05% |
| 2016-12-31 | CN¥4.83 Billion ≈ $706.06 Million |
+42.95% |
| 2015-12-31 | CN¥3.38 Billion ≈ $493.93 Million |
+113.93% |
| 2014-12-31 | CN¥1.58 Billion ≈ $230.88 Million |
+674.17% |
| 2013-12-31 | CN¥203.80 Million ≈ $29.82 Million |
-5.00% |
| 2012-12-31 | CN¥214.53 Million ≈ $31.39 Million |
+257.69% |
| 2011-12-31 | CN¥59.98 Million ≈ $8.78 Million |
-42.02% |
| 2010-12-31 | CN¥103.44 Million ≈ $15.14 Million |
-66.23% |
| 2009-12-31 | CN¥306.33 Million ≈ $44.83 Million |
+13.00% |
| 2008-12-31 | CN¥271.09 Million ≈ $39.67 Million |
+143.60% |
| 2007-12-31 | CN¥111.28 Million ≈ $16.28 Million |
-56.81% |
| 2006-12-31 | CN¥257.68 Million ≈ $37.71 Million |
-- |
About Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products,… Read more